Although the combination of anti-VEGF antibody in ICI suppressed to occurrence of HPD and negative clinical impact of HPD was reduced in patients with advanced HCC, elucidation of the HPD mechanism in ICI combined with anti-VEGF antibody and identification of its predictors are strongly required in patients with advanced HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.